Sangamo showcases progress in our pre-clinical programs at ASGCT.
Click here to view
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
Science
Overview
Zinc Fingers
Cell Therapy
Genome Regulation
Bioethics
Publications
Presentations
Manufacturing Capabilities
Programs
Programs
Pipeline
Clinical Trials
Collaborations
Patients
Our Commitment
Patient Stories
Bioethics
Resources
Investors & Media
Overview
News Releases
Events
Presentations
ESG
Careers
Core Values
Open Positions
Culture
Employee Benefits
About
Inside Sangamo
Latest News
Connect
LinkedIn
Twitter
Inherited Metabolic Diseases
Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.
August 24th, 2018
In vivo genome editing of the albumin locus as a platform for protein replacement therapy.
August 24th, 2018